In 2023, Insmed anticipates that over 80% of total expenditures will be on its mid-to-late stage and commercial programs (ARIKAYCE, brensocatib, and TPIP), and that less than 20% of overall spend will be on its early-stage research programs, reflecting the company’s historical approach to spending.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSM: